MARKET

IMGN

IMGN

Immunogen Inc
NASDAQ
5.08
-0.07
-1.36%
After Hours: 5.08 0 0.00% 17:27 11/28 EST
OPEN
5.13
PREV CLOSE
5.15
HIGH
5.27
LOW
5.07
VOLUME
3.45M
TURNOVER
0
52 WEEK HIGH
7.77
52 WEEK LOW
3.095
MARKET CAP
1.12B
P/E (TTM)
-6.2324
1D
5D
1M
3M
1Y
5Y
Looking Into Immunogen's Return On Capital Employed
Benzinga · 9h ago
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
Benzinga · 5d ago
Truist Securities Initiates Coverage On Immunogen with Buy Rating, Announces Price Target of $10
Benzinga · 11/21 13:00
BRIEF-Immunogen Appoints Daniel Char As Senior Vice President And Chief Legal Officer
Reuters · 11/21 11:36
Truist Securities Initiates Coverage on ImmunoGen at Buy With $10 Price Target
Truist Securities Initiates Coverage on ImmunoGen at Buy With $10 Price Target
MT Newswires · 11/21 10:38
ImmunoGen Names Daniel Char as Chief Legal Officer
ImmunoGen Names Daniel Char as Chief Legal Officer
MT Newswires · 11/21 06:56
NeoGenomics And ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access To Novel FR Biomarker Testing To Support the Launch Of ELAHERE
Benzinga · 11/18 14:21
NeoGenomics Introduces ImmunoGen-backed Test Program for Epithelial Ovarian Cancer
NeoGenomics Introduces ImmunoGen-backed Test Program for Epithelial Ovarian Cancer
MT Newswires · 11/18 12:32
More
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Mirvetuximab soravtansine is a first-in-class ADC targeting folate receptor alpha (FRα), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. IMGN632 (Pivekimab sunirine) is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. It is advancing pivekimab in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.